EUVIMEDScopri EUVIMED
Systematische ÜbersichtOpen access · CC BY 4.0

Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review

Rachel L Sagar, Lilian Walther-Jallow, Cecilia Götherström, Magnus Westgren, Anna L David iD

Prenatal Diagnosis · 2023

DOI: 10.1002/pd.6459 ↗

At a glance

Systematische Übersicht in Prenatal Diagnosis, 2023. Written by Rachel L Sagar and 4 co-authors. Institution: Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK. Major MEDLINE topics: Pregnancy Outcome, Prenatal Care. Cited 4 times so far (Crossref); 89 references. The full text is freely available (open access, CC BY 4.0). Funded by: EIT Health.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

To investigate the maternal and fetal safety of In utero stem cell transplantation (IUSCT).

Methods

Medline®, Embase and Cochrane library (1967−2023) search for publications reporting IUSCT in humans. Two reviewers independently screened abstracts and full‐text papers.

Results

Sixty six transplantation procedures in 52 fetuses were performed for haemoglobinopathies ( n = 14), red cell/bleeding disorders ( n = 4), immunodeficiencies ( n = 15), storage disorders ( n = 7), osteogenesis imperfecta ( n = 2) and healthy fetuses ( n = 10). The average gestational age was 18.9 weeks; of procedures reporting the injection route, cells were delivered by intraperitoneal ( n = 37), intravenous ( n = 19), or intracardiac ( n = 4) injection or a combination ( n = 3); most fetuses received one injection ( n = 41). Haematopoietic ( n = 40) or mesenchymal ( n = 12) stem cells were delivered. The cell dose was inconsistently reported (range 1.8−3.3 × 10 9 cells total ( n = 27); 2.7−5.0 × 10 9 /kg estimated fetal weight ( n = 17)). The acute fetal procedural complication rate was 4.5% (3/66); the acute fetal mortality rate was 3.0% (2/66). Neonatal survival was 69.2% (36/52). Immediate maternal and pregnancy outcomes were reported in only 30.8% (16/52) and 44.2% (23/52) of cases respectively. Four fetal/pregnancy outcomes would also classify as ≥ Grade 2 maternal adverse events.

Conclusions

Short‐, medium‐, and long‐term maternal and fetal adverse events should be reported in all IUSCT studies.

Subjects

MeSH terms (MEDLINE)

Pregnancy OutcomePrenatal CarePregnancyInfant, NewbornFemaleHumansInfantFetusGestational Age

Authors and institutions

  • Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
  • Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institutet, ANA Futura, Huddinge, Sweden.
  • NIHR University College London Hospitals Biomedical Research Centre, London, UK.

ORCID profiles: Anna L David

Funding

  • EIT Health

Cite

APA

Sagar, R. L., Walther-Jallow, L., Götherström, C., Westgren, M., & David, A. L. (2023). Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review. Prenatal Diagnosis. https://doi.org/10.1002/pd.6459

Vancouver

Sagar RL, Walther-Jallow L, Götherström C, Westgren M, David AL. Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review. Prenatal Diagnosis. 2023. doi:10.1002/pd.6459

BibTeX
@article{Sagar2023,
  author = {Sagar, Rachel L and Walther-Jallow, Lilian and Götherström, Cecilia and Westgren, Magnus and David, Anna L},
  title = {Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review},
  journal = {Prenatal Diagnosis},
  year = {2023},
  doi = {10.1002/pd.6459}
}
Start for free →